AGP Executive Report
Last update: 4 hours agoInfluenza Vaccines: Liège-based Osivax says its Phase 2b trial of OVX836 missed its main target, with a non-significant 24% efficacy estimate. The company will pursue the vaccine in combination with standard seasonal shots. GSK Jobs: The drugmaker plans up to 1,217 job cuts at its Belgian sites, while saying Belgium will still produce most of its vaccines. Heart Care: A new EU-backed research project will run 22 clinical studies involving more than 14,000 patients to test earlier, personalised cardiovascular care. Belgian Biotech: Mechelen-based Lakefront has sold preclinical cancer cell-therapy programmes to Belgian firm Armed Cell Therapeutics, with potential milestone payments of up to $230 million. Local Health Risks: Brussels has launched legal action over severe PFAS pollution in Uccle; Belgium’s suicide-prevention centre also warns of worsening mental health among young people. Health Research: A ULB-led study found sex hormones influence how skin stem cells renew, a finding that could inform research into inflammatory disease and cancer. Belgium’s share of deaths attributed to euthanasia reportedly reached 4% in 2025, more than double the level five years earlier.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
